According to the American Cancer Society, nearly 2 million people living in the United States will be diagnosed with cancer in 2022, and roughly one in three people will be diagnosed with cancer in their lifetime.
Annually, 21% of all new cancer cases diagnosed are lung and bronchus cancer. The high prevalence and aggressiveness of this form of cancer render it most deadly. Each year, lung and bronchus cancer causes 3 times the number of deaths of colorectal cancer, the second most deadly cancer.
Research has shown that several preventative steps can be taken to lower your risk of lung and bronchus cancer. The Mayo Clinic recommends the following:
Upon diagnosis of lung cancer in a patient, chemotherapy is generally included in the plan to treat and combat the disease.
Unfortunately, traditional chemotherapy cannot differentiate between cancerous and healthy cells, rendering healthy cells subject to the same fate as cancer cells, in some instances.
A wide array of adverse side effects — including hair loss, loss of appetite, nausea, and fatigue to name a few — accompany chemotherapy treatment, negatively impacting a patient’s overall quality of life.
According to National Cancer Institute statistics, new cases of lung and bronchus cancer have decreased over the past decade. Overall awareness and an increase in healthy life choices have facilitated a downward trend in new cases diagnosed annually.
During this same period, the overall survival rate among lung and bronchus cancer patients has seen a marked increase due to advancements in the ways medical science is able to detect disease and personalize treatment.
Members of our Donor Community continue to afford researchers and drug discovery entities the opportunity to improve upon advancements made in the realm of biomarker testing.
Biomarker testing has been shown to be effective in the prediction and early detection of cancer. It:
The information obtained through biomarker testing has allowed:
As more knowledge is gained through research thanks to body donors, biomarker testing should continue to advance and: